Quote:

---

ohm: how reasonable would it be to assume that your assessment, regarding this lack of resistance to LL treatment, would be commonly understood within the research and Keytruda focused communities at MRK (given the prior Keytruda/LL mouse study)?

---

I'm certain they tested for PD-1 receptor occupancy by Keytruda. If Merck realized prior that leronlimab downregulates PD-L1 and could replace Keytruda they probably wouldn't have done the study.

It being preclinical they may or may not have tested for PD-L1 levels. If they didn't test they probably still don't realize the downregulation of PD-L1 and would have no reason to think about no resistance. If they did test for PD-L1 and realize that it was caused by leronlimab they would keep it quiet. If they were really smart they'd make an offer now but they and other pharma companies might wait for confirmation from a new phase 2 cancer trial.